Bendamustine

Section: 8. Immunomodulators and antineoplastics > 8.2. Antineoplastics and supportive medicines > 8.2.1. Cytotoxic medicines

Codes ATC: L01AA09

Indication	Follicular lymphoma Code ICD11: 2A80.Z
INN	Bendamustine
Type de médicament	Chemical agent
Type de liste	Liste complémentaire
Formulations	**Parenteral > General injections > unspecified:** 45 mg per 0.5 mL ; 180 mg per 2 mL
Historique des statuts LME	Ajouté pour la première fois en 2015 (TRS 994)
Sexe	Tous
Âge	Adolescents et adultes
Équivalence thérapeutique	La recommandation concerne ce médicament spécifique
Renseignements sur le brevet	Main patents have expired but secondary patents might remain active in some jurisdictions. For more information on specific patents and license status for developing countries visit www.MedsPal.org Lire la suite sur les brevets.
Balises	Cancer
Wikipédia	Bendamustine
DrugBank	Bendamustine

Résumé des preuves et recommandation du comité d'experts

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, bendamustine was added to the complementary list of the EML for use in treatment protocols for follicular lymphoma. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for follicular lymphoma is attached.